Avatar for Atomwise

AI for drug discovery

AI for drug discovery

Atomwise uses artificial intelligence to help discover new medicines and agricultural compounds. Its groundbreaking AtomNet technology reasons like a human chemist, using powerful deep learning algorithms and supercomputers to analyze millions of potential molecules each day. Atomwise has launched more than 50 discovery projects in partnership with the world’s top research companies and universities. Now, through its many partnering programs and robust venture funding, Atomwise is actively seeking new collaborators to address the global health challenges of our time using the power of artificial intelligence.

Atomwise hasn't added any jobs yet

Get notified when Atomwise posts new jobs.

See similar jobs

Latest Stories and News

Atomwise's machine learning-based drug discovery service raises $123 million

  • TechCrunch
  • 1 month ago
  • Atomwise has raised $123 million in new funding to accelerate its business.
  • B Capital and Sanabil Investments combined to lead Atomwise’s Series B round. DCVC, BV, Tencent, Y Combinator, Dolby Ventures, AME Cloud Ventures and two, undisclosed, insurance companies have invested in the company’s latest round.
  • The power of Atomwise’s drug discovery platform is its ability to harness machine learning to structure new proteins that have never existed — and ensure that they’re able to reach precise target receptors to accomplish a desired task.
  • The company plans to continue to expand its work with corporate partners, which currently include major players in the biopharma space including Eli Lilly and Company, Bayer, Hansoh Pharmaceuticals, and Bridge Biotherapeutics, as well as emerging biotechnology companies like StemoniX and SEngine Precision Medicine.
Atomwise's machine learning-based drug discovery service raises $123 million
Total raised


Funded over

2 rounds

Latest round

Series A (Mar 2018)